Bone Therapeutics receives clearance for ALLOB® phase II trial in spine fusion Read more about Bone Therapeutics receives clearance for ALLOB® phase II trial in spine fusion
Bone Therapeutics extends ALLOB® phase I/IIa trial to Germany Read more about Bone Therapeutics extends ALLOB® phase I/IIa trial to Germany
Bone Therapeutics and Kasios to collaborate on novel product for the optimisation of spinal fusion procedures Read more about Bone Therapeutics and Kasios to collaborate on novel product for the optimisation of spinal fusion procedures
Bone Therapeutics Authorised to Enrol patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB® Read more about Bone Therapeutics Authorised to Enrol patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB®
Bone Therapeutics Expands Product Portfolio with New Research into Innovative Combined Cell-Matrix Product Read more about Bone Therapeutics Expands Product Portfolio with New Research into Innovative Combined Cell-Matrix Product
Bone Therapeutics Announces Intention to Launch an Initial Public Offering on Euronext Brussels and Euronext Paris Read more about Bone Therapeutics Announces Intention to Launch an Initial Public Offering on Euronext Brussels and Euronext Paris
Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB® Phase I/IIA Delayed-Union Trial Read more about Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB® Phase I/IIA Delayed-Union Trial
Bone Therapeutics Launches its Initial Public Offering on Euronext Brussels and Euronext Paris Read more about Bone Therapeutics Launches its Initial Public Offering on Euronext Brussels and Euronext Paris
Bone Therapeutics raises EUR32.2M in a 2.5x oversubscribed successful Initial Public Offering on Euronext Brussels and Euronext Paris Read more about Bone Therapeutics raises EUR32.2M in a 2.5x oversubscribed successful Initial Public Offering on Euronext Brussels and Euronext Paris
Full exercise of Over-allotment Option: Total proceeds from the Initial Public Offering increased to €37 million Read more about Full exercise of Over-allotment Option: Total proceeds from the Initial Public Offering increased to €37 million
